Serdexmethylphenidate

KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

Retrieved on: 
Thursday, June 3, 2021
Psychoactive drugs, Stimulants, Nootropics, Euphoriants, Methylphenidate, Amphetamine, Serdexmethylphenidate, Attention deficit hyperactivity disorder, Idiopathic hypersomnia, Drug, Benzhydrocodone, Dexmethylphenidate

KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH).

Key Points: 
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH).
  • KemPharms lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX).
  • In addition, KemPharm has received FDA approval for AZSTARYSTM, a new once-daily treatment for ADHD in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”

Retrieved on: 
Wednesday, January 13, 2021
Psychoactive drugs, Stimulants, Euphoriants, Nootropics, Piperidines, Phenethylamines, Methylphenidate, Benzhydrocodone, Dexmethylphenidate, Attention deficit hyperactivity disorder, Serdexmethylphenidate, Hydrocodone

KP415 consists of serdexmethylphenidate (SDX), KemPharms prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.

Key Points: 
  • KP415 consists of serdexmethylphenidate (SDX), KemPharms prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.